Skip to content
The biotech IPO outlook is strong, say experts
Biotech CEOs weathering a lean investment market got some good news from a panel of experts on Feb. 27. Following a couple of painfully […]
The biotech IPO outlook is strong, say experts Read More »
Health
WTO Ministerial ends, no expansion of COVID IP waiver
The World Trade Organization (WTO) 13th Ministerial concluded on Friday, March 1, without an agreement to expand the COVID-19 intellectual property waiver to therapeutics
WTO Ministerial ends, no expansion of COVID IP waiver Read More »
Could CRISPR be the answer to sickle cell disease?
Sickle cell disease (SCD) patients were given new hope in late 2023 when the Food and Drug Administration (FDA) approved two novel treatments. One
Could CRISPR be the answer to sickle cell disease? Read More »
As White House prepares ‘listening session’ on PBMs, here’s what they need to hear
On Monday, March 4, the White House will host a “listening session” on the impact of Pharmacy Benefit Managers (PBMs). This is a welcome
As White House prepares ‘listening session’ on PBMs, here’s what they need to hear Read More »
Lawmakers back bipartisan legislation supporting rare disease research
Bipartisan legislation to support research into rare diseases received backing from witnesses and lawmakers during a Feb. 29 hearing of the House Energy and
Lawmakers back bipartisan legislation supporting rare disease research Read More »
Biotech investment is scarce, but still available, experts tell CEOs
Even in this challenging market, biotechnology firms are attracting investment and building capital, but they need more than just a great innovation. They also
Biotech investment is scarce, but still available, experts tell CEOs Read More »
What biotech companies should know about M&A in down markets
Mergers and acquisitions (M&A) are important elements of the biotech industry, especially for early-stage fundraising and bringing new drugs and treatments to the market.
What biotech companies should know about M&A in down markets Read More »
The future of next-generation obesity drugs
The metabolic field is the hottest biotech therapeutic area of the year (and likely to continue beyond). In the context of a difficult couple
The future of next-generation obesity drugs Read More »
CEOs ask Congress to pass ORPHAN Cures Act
Biotechnology Innovation Organization (BIO) member companies and CEOs sent a letter to congressional leaders urging them to pass the bipartisan ORPHAN Cures Act and
CEOs ask Congress to pass ORPHAN Cures Act Read More »
Drug developers and investors need to join AI revolution, panel says
Artificial intelligence and machine learning have boosted drug development and enhanced the value of biotech firms for years, but investors and companies need to
Drug developers and investors need to join AI revolution, panel says Read More »